{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SGLT-2+inhibitor",
    "query": {
      "intervention": "SGLT-2 inhibitor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 136,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SGLT-2+inhibitor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T15:46:30.116Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05435235",
      "title": "Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Kidney Injury",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10mg Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein Healthcare Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-09-01",
      "completion_date": "2025-06",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05435235"
    },
    {
      "nct_id": "NCT03970044",
      "title": "Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Exenatide 2 MG",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Consano Clinical Research, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 67,
      "start_date": "2019-07-02",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-08-30",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 1,
      "location_summary": "Shavano Park, Texas",
      "locations": [
        {
          "city": "Shavano Park",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970044"
    },
    {
      "nct_id": "NCT06350123",
      "title": "Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2024-05-01",
      "completion_date": "2025-05-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 15,
      "location_summary": "Sheffield, Alabama • Glendale, California • Waterbury, Connecticut + 10 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06350123"
    },
    {
      "nct_id": "NCT02597049",
      "title": "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dulaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 424,
      "start_date": "2015-11",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2020-06-17",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 13,
      "location_summary": "Encino, California • Huntington Park, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02597049"
    },
    {
      "nct_id": "NCT00642278",
      "title": "An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type II",
        "Diabetes Mellitus, Non Insulin Dependent"
      ],
      "interventions": [
        {
          "name": "Canagliflozin (JNJ-28431754)",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 451,
      "start_date": "2008-04",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2013-07-19",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00642278"
    },
    {
      "nct_id": "NCT06229678",
      "title": "Ketones, SGLT2, HFrEF",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type2diabetes",
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Empagliflozin 25 MG Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Acipimox 250 Mg Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 71,
      "start_date": "2024-01-25",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06229678"
    },
    {
      "nct_id": "NCT05526157",
      "title": "An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Finerenone (Kerendia, BAY 948862)",
          "type": "DRUG"
        },
        {
          "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)",
          "type": "DRUG"
        },
        {
          "name": "Steroidal mineral corticoid receptor antagonists (sMRA)",
          "type": "DRUG"
        },
        {
          "name": "Non-steroidal mineral corticoid receptor antagonists (nsMRA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50000,
      "start_date": "2022-10-01",
      "completion_date": "2024-09-05",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 1,
      "location_summary": "Eden Prairie, Minnesota",
      "locations": [
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05526157"
    },
    {
      "nct_id": "NCT05390892",
      "title": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type2Diabetes",
        "ASCVD"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 6000,
      "start_date": "2022-09-26",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 36,
      "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05390892"
    },
    {
      "nct_id": "NCT06932081",
      "title": "Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adult Congenital Heart Disease",
        "Congenital Heart Disease",
        "Systemic Right Ventricle",
        "Transposition of the Great Arteries",
        "Congenitally Corrected Transposition of the Great Arteries",
        "Fontan",
        "Single Ventricle",
        "Tetralogy of Fallot (TOF)"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leiden University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2023-01-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Grand Rapids, Michigan • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06932081"
    },
    {
      "nct_id": "NCT05885074",
      "title": "Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Weight Loss"
      ],
      "interventions": [
        {
          "name": "Empagliflozin Arm",
          "type": "DRUG"
        },
        {
          "name": "Control Arm",
          "type": "OTHER"
        },
        {
          "name": "Exercise capacity VO2 maximum determination",
          "type": "OTHER"
        },
        {
          "name": "Exercise Challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-01-30",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-09-16T15:46:30.116Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05885074"
    }
  ]
}